Get the Stockscreener App
21.08
2.53%
0.52
Catalyst Pharmaceuticals Inc stock is traded at $21.08, with a volume of 1.11M.
It is up +2.53% in the last 24 hours and up +0.86% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$20.56
Open:
$20.72
24h Volume:
1.11M
Relative Volume:
0.85
Market Cap:
$2.58B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
17.86
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+4.20%
1M Performance:
+0.86%
6M Performance:
-2.50%
1Y Performance:
+1.64%
1-Day Range:
$20.63
$21.28
1-Week Range:
$19.92
$21.28
52-Week Range:
$19.00
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.08 | 2.48B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Risk adjusted return profile for Catalyst Pharmaceuticals Inc. analyzed2025 Institutional Moves & Consistent Profit Trade Alerts - Newser
How moving averages guide Catalyst Pharmaceuticals Inc. tradingJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Vanguard Group Inc. Buys 64,486 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Published on: 2025-08-20 03:26:00 - Newser
Is Catalyst Pharmaceuticals Inc. stock entering bullish territory2025 Sector Review & Growth Oriented Trade Recommendations - Newser
Catalyst Pharmaceuticals Inc. stock prediction for this weekLayoff News & Community Consensus Stock Picks - Newser
How to recover losses in Catalyst Pharmaceuticals Inc. stockGold Moves & Real-Time Chart Breakout Alerts - Newser
Published on: 2025-08-19 23:16:32 - Newser
Is it time to cut losses on Catalyst Pharmaceuticals Inc.Quarterly Portfolio Review & Entry Point Confirmation Signals - Newser
How to escape a deep drawdown in Catalyst Pharmaceuticals Inc.Rate Hike & Daily Growth Stock Investment Tips - Newser
Volume spikes in Catalyst Pharmaceuticals Inc. stock – what they mean2025 Retail Activity & High Accuracy Trade Signal Alerts - Newser
Strategies to average down on Catalyst Pharmaceuticals Inc.July 2025 Breakouts & Reliable Trade Execution Plans - Newser
What data driven models say about Catalyst Pharmaceuticals Inc.’s futureMarket Growth Summary & Stock Portfolio Risk Control - Newser
Published on: 2025-08-19 06:55:29 - Newser
How to track smart money flows in Catalyst Pharmaceuticals Inc.2025 Market Sentiment & Short-Term High Return Ideas - Newser
Sector Leaders Rotate Capital Into Catalyst Pharmaceuticals Inc.2025 Big Picture & Free Community Supported Trade Ideas - kangso.co.kr
What technical models suggest about Catalyst Pharmaceuticals Inc.’s comeback2025 Top Gainers & Long-Term Growth Stock Strategies - Newser
Identifying reversal signals in Catalyst Pharmaceuticals Inc.2025 Buyback Activity & Daily Profit Maximizing Trade Tips - Newser
What high frequency data says about Catalyst Pharmaceuticals Inc.2025 Institutional Moves & Weekly Watchlist for Consistent Profits - Newser
Published on: 2025-08-17 22:31:22 - Newser
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyJuly 2025 Snapshot & Fast Moving Stock Watchlists - Newser
Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) PT at $33.20 - Defense World
Is Catalyst Pharmaceuticals Inc. still worth holding after the dip2025 Top Decliners & Daily Profit Focused Screening - Newser
Catalyst Pharmaceuticals Inc.’s volatility index tracking explained2025 Buyback Activity & Free Long-Term Investment Growth Plans - Newser
What is the next catalyst for EyePoint Pharmaceuticals Inc.Rate Hike & Technical Pattern Recognition Alerts - thegnnews.com
Does Catalyst Pharmaceuticals Inc. show high probability of rebound - Newser
Catalyst Pharmaceuticals Inc. stock trendline breakdownMarket Trend Review & Community Shared Stock Ideas - Newser
US Bancorp DE Has $178,000 Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Smart tools for monitoring Catalyst Pharmaceuticals Inc.’s price actionMarket Performance Summary & Fast Moving Stock Watchlists - Newser
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Yahoo Finance
Catalyst Pharmaceuticals (NASDAQ:CPRX) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point - Yahoo Finance
Catalyst Pharmaceuticals: A Cheap but Developing Biopharma Name - AInvest
Catalyst Pharmaceuticals: A Developing Story That's Cheap Enough (NASDAQ:CPRX) - Seeking Alpha
Catalyst Pharmaceuticals shares rise 2.54% intraday after Xenon Pharmaceuticals reports positive Phase 3 study progress and commercial leadership appointment. - AInvest
Why Catalyst Pharmaceuticals Inc. stock is on top investor watchlistsFree Consistent Profit Pattern Recognition Tools - Newser
Catalyst Pharmaceuticals shares rise 1.26% premarket due to growth in Sterilization Medical Packaging Market. - AInvest
XTX Topco Ltd Sells 15,179 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Cetera Investment Advisers Has $1.41 Million Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Catalyst Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Catalyst Pharmaceuticals reaffirms $545M-$565M 2025 revenue guidance while accelerating FIRDAPSE oncology expansion - MSN
Catalyst Pharma Receives Buy Rating and Price Target of $34.00 from Bank of America Securities Analyst Jason Gerberry. - AInvest
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y - MSN
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to “Hold” at Wall Street Zen - Defense World
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharma Reports Record Q2 2025 Financial Results - The Globe and Mail
Catalyst Pharma Updates Guidelines for SCLC Treatment - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: Catalyst Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com South Africa
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sundaram Preethi | Chief Strategy Officer |
Jun 11 '25 |
Sale |
26.42 |
1,600 |
42,272 |
41,081 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):